Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;19(10):727-736.
doi: 10.2217/fon-2022-1287. Epub 2023 May 3.

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Seda Kahraman  1 , Enes Erul  2 , Mustafa Seyyar  3 , Ozge Gumusay  4 , Ertugrul Bayram  5 , Burcin Cakan Demirel  6 , Omer Acar  7 , Sercan Aksoy  2 , Naziyet Kose Baytemur  8 , Elif Sahin  3 , Devrim Cabuk  3 , Gul Basaran  4 , Semra Paydas  5 , Arzu Yaren  6 , Deniz Can Guven  2 , Atike Pinar Erdogan  7 , Umut Demirci  8 , Alper Yasar  9 , İbrahim Vedat Bayoglu  9 , Mutlu Hizal  1 , Burcu Gulbagci  10 , Nail Paksoy  11 , Sena Ece Davarci  12 , Funda Yilmaz  13 , Ozlem Dogan  14 , Sibel Oyucu Orhan  15 , Erkan Kayikcioglu  16 , Ali Aytac  17 , Merve Keskinkilic  18 , Eda Eylemer Mocan  19 , Olcun Umit Unal  20 , Esra Aydin  21 , Hakan Yucel  22 , Deniz Isik  23 , Onder Eren  24 , Basak Oyan Uluc  4 , Melike Ozcelik  25 , Ilhan Hacibekiroglu  10 , Adnan Aydiner  11 , Hacer Demir  12 , Berna Oksuzoglu  13 , Ebru Cilbir  14 , Erdem Cubukcu  15 , Bulent Cetin  16 , Esin Oktay  17 , Cihan Erol  1 , Sadi Kerem Okutur  26 , Nilgun Yildirim  27 , Ali Alkan  28 , Fatih Selcukbiricik  29 , Asude Aksoy  30 , Yusuf Karakas  31 , Gulhan Ozkanli  32 , Berna Bozkurt Duman  33 , Dincer Aydin  34 , Ozgecan Dulgar  35 , Muhammed Muhiddin Er  36 , Fatih Teker  22 , Tugba Yavuzsen  18 , Musa Baris Aykan  37 , Ali Inal  38 , Yakup Iriagac  39 , Nurhan Onal Kalkan  40 , Murat Keser  20 , Teoman Sakalar  35 , Serkan Menekse  41 , Engin Kut  41 , Burak Bilgin  42 , Muge Karaoglanoglu  43 , Veli Sunar  44 , Ozlem Ozdemir  45 , Nazim Serdar Turhal  46 , Nuri Karadurmus  37 , Bulent Yalcin  1 , Mehmet Ali Nahit Sendur  1
Affiliations

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Seda Kahraman et al. Future Oncol. 2023 Mar.

Abstract

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.

Keywords: CDK 4/6 inhibitors; HER2-negative metastatic breast cancer; HR-positive; letrozole.

PubMed Disclaimer

LinkOut - more resources